Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
221
resultados
Última actualización
01/05/2026 [07:09:00]
Resultados 200 a 221 de 221
Resumen de: AU2026202277A1
Abstract Disclosed therein are mannan nanogels as a novel vaccine delivery platform as well as a novel method of making a self-assembling mannan nanogel for in vivo delivery of therapeutic agents.
Resumen de: US20260102362A1
Described are methods for reducing the formation of amphetamine carbamate and amphetacarbamate in transdermal amphetamine compositions, compositions with low levels of amphetacarbamate, and methods using such compositions for transdermal delivery of amphetamine.
Resumen de: AU2025271161A1
The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors. ov o v
Resumen de: US20260102349A1
Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.
Resumen de: WO2026079308A1
The present invention provides: lipid nanoparticles that include a nucleic acid, cKK-E12, and DOPC, the molar ratio of the cKK-E12 to the DOPC content being 0.2–15.0; and a production method for the lipid nanoparticles that includes a step for preparing a lipid solution that includes cKK-E12, DOPC, a sterol, and a PEG lipid, a step for preparing a nucleic acid solution that includes a nucleic acid, and a step for mixing the lipid solution and the nucleic acid solution.
Resumen de: WO2026078426A1
A targeted nanocarrier for delivering drugs to targeted cells. The targeted nanocarrier may comprise a nano-colloid suspension of poly(phenyllactic-co-kojic-co-gluconic acid) (poly(PLKGA)), the nano colloid suspension of poly(PLKGA) comprising: a dispersed phase comprising a plurality of nanoparticles of poly(PLKGA); and a continuous phase comprising a medium of the nano-colloid suspension of poly(PLKGA).
Resumen de: WO2026077978A1
The present invention relates to nanoparticles capable of crossing biological barriers. In particular, it refers to lipid nanoparticles configured to cross the blood-brain barrier, target skeletal tissues and effectively penetrate the skin barrier. The invention also encompasses compositions and applications thereof.
Resumen de: WO2026078444A1
The disclosure relates to the development of a nano-encapsulated extract of Mitragyna speciosa, commonly known as kratom, specifically designed for use in beverages, dietary supplements and natural health products. This extract is standardized to contain a precise concentration of mitragynine, the primary active alkaloid in kratom, ensuring consistent potency and efficacy in enhancing energy, alertness, and alleviating minor pain, such as delayed inset muscle soreness, associated with physical exertion. The disclosed technology outlines an extraction and encapsulation process that not only maximizes the yield of mitragynine but also ensures the removal of undesirable compounds and the encapsulation provides improved bioavailability, thereby enhancing the safety profile of the final product. The standardized extract may be easily incorporated into various beverage formulations, dietary supplements and natural health products, providing a reliable and effective herbal supplement option.
Resumen de: US20260102452A1
The invention introduces a nanoemulsion-based nanocream formulated from green ingredients, designed to improve performance, stability, and sustainability. The nanoemulsion is developed using the low-energy Phase Inversion Temperature (PIT) method, which leverages the system's internal chemical energy to minimize external energy input, protect heat-sensitive compounds, and lower production costs. During PIT, polyethoxylated surfactants, hydrophilic at lower temperatures, become lipophilic when heated as their polyoxyethylene groups dehydrate, triggering phase inversion from oil-in-water (O/W) to water-in-oil (W/O). Rapid cooling with continuous stirring reverts to the O/W phase, causing turbulence and generating a stable nanoemulsion with nano-sized droplets of high uniformity. This nanoemulsion replaces water in the cream's aqueous phase, forming a nanocream that enhances bioactive delivery to the skin. The cream's thick, highly viscous oily base minimizes the risk of coalescence and further improves the overall stability of the nano-sized droplets containing bioactive oils.
Resumen de: WO2026077099A1
Provided are a protein/polyester/lipid-nucleic acid delivery system for delivering a nucleic acid drug, a preparation method therefor, and use thereof. The system is prepared from an aqueous phase comprising a nucleic acid and a protein, and an organic phase comprising a hydrophobic degradable aliphatic polyester and a derivative thereof, and an ionizable lipid and/or a cationic lipid material. The preparation method comprises mixing an aqueous phase and an organic phase by using a single emulsification technology or a high-pressure homogenization technology to obtain a protein nanoassembly for targeted nucleic acid delivery. The protein is albumin or a single-chain antibody-albumin fusion protein. The stable protein nanoassembly is applied to a targeted nucleic acid delivery platform, and is applied to a nucleic acid treatment drug for tumors, autoimmune diseases, or inflammatory diseases.
Resumen de: DE102024129442A1
Die Erfindung betrifft ein Konjugat umfassend mindestens ein Polymer und mindestens einen Antikörper oder mindestens ein Antikörperfragment, wobei das Polymer ausgewählt ist aus Poly(dimethyl acrylamid) (PDMA), Poly(oligoethylen glykol methacrylat) (POEGMA), Poly(2-hydroxypropyl methacrylamid) (PHPMA), Poly(vinylpyrrolidon) (PVP), Poly(2-methylsulfinyl)ethyl acrylat (PMSEA), Poly(6-O-methacyloyl-D-galactopyranose) (PMAGP), Acrylsäure (PAA), Poly(carboxybetain acrylat) (PCBA), Poly(vinylphosphonsäure) (PVPA), Poly(vinylbenzoesäure) (PVBzA), Poly(propylacrylsäure) (PPAA), Poly(styrolsulfonsäure) (PSS), Polyglycerol (PG) und Polyäpfelsäure (PMA) und das mindestens eine Antikörperfragment vorzugsweise mindestens einen Einzeldomänenantikörper (Nanobody) umfasst. Die Erfindung betrifft ferner die medizinische Verwendung des Konjugats, sein Herstellungsverfahren und Kits für dessen Anwendung.
Resumen de: US20260102509A1
A nanoparticle compound comprising buckminsterfullerene C60 bonded to ester functional groups of pyruvic, citric, and hyaluronic acids, with oxygen-bridged components selected from vanadium, gallium, and bismuth is provided. At least one component enables quantum-mechanical spin-wave activation. Ultrasonic irradiation activates the compound, inducing electrical induction for tissue healing and cell growth. The compound integrates with native and 3D-printed tissues, enhancing their properties through interpenetrating networks. It exhibits anti-inflammatory, antioxidant, and antibacterial effects, reinforces connective tissue, and modulates stem cell growth. The compound treats arthritis, enhances gut health and barrier function, supports bone health, improves voice quality, counters cancer cell proliferation, and mitigates osteoporosis. The gallium component creates an alkaline environment for calcium deposition, while vanadium enhances chondrogenic differentiation. Administration methods include topical application, oral ingestion, injection, and infusion through bandages or sutures. The compound serves as an adjuvant for analgesics, enhancing their delivery and efficacy.
Resumen de: WO2026080471A2
The disclosure relates generally to tRNA-based effector molecules and conjugates thereof comprising moieties (e g., carbohydrates, lipids, peptides, small molecules, oligonucleotides) and methods, compositions, and uses relating thereto.
Resumen de: WO2026080839A1
Immunoreactive peptides that can be used to detect or generate an immune response against Ehrlichia bacteria are provided. The immunoreactive peptides may be included in a diagnostic kit or pharmaceutical composition or vaccine composition. Methods of diagnosing or detecting exposure to E. canis in a mammalian subject, such as a dog, are also provided.
Resumen de: WO2026078579A1
The present disclosure encompasses a lipid nanoparticle (LNP) comprising a polypeptide comprising a nucleic acid sequence encoding an engineered meganuclease that binds and cleaves a recognition sequence within a Hepatitis B virus (HBV) genome. Further, the disclosure encompasses pharmaceutical compositions comprising the LNPs, and the use of such compositions for inactivating a pol gene of an HBV genome or an HBV genome fragment in a cell and treating HBV infections or diseases associated with HBV infections.
Resumen de: WO2026080826A1
The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., hematopoietic stem cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
Resumen de: WO2026080557A1
Disclosed are lipidoid compounds having the structure of formula (I): or a salt thereof, wherein the groups are as defined in the application. Also disclosed are nanoparticle compositions comprising a lipidoid of the invention that are capable of delivering a therapeutic agent. The application also discloses pharmaceutical compositions comprising a lipidoid composition of the invention.
Resumen de: WO2026080622A1
Provided herein are compounds, such as compounds of Formula (I), and compositions, methods, uses, and kits thereof. The compounds provided herein are lipids useful for delivery of therapeutic cargo (e.g., polynucleotides, such as mRNA). In particular, the compounds described herein may be incorporated into lipid-based compositions to increase efficiency of delivery of a therapeutic agent(s) to a cell, a tissue, or a subject.
Resumen de: AU2024359608A1
The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.
Resumen de: AU2024382503A1
A modified myoferlin protein capable of being packaged into extracellular vesicles (EVs) to facilitate release of EV payloads into recipient cells. The modified myoferlin protein enhances the release of payload at the targeted site. The present invention further provides a modified myoferlin-encapsulating nanoparticle comprising an exosome encapsulating any embodiment of the modified myoferlin of the present invention and one or more cargo RNAs to enhance release of the cargo RNAs at the targeted site.
Nº publicación: AU2024342596A1 16/04/2026
Solicitante:
DSCILAB CO LTD
Resumen de: AU2024342596A1
The present invention relates to a material for local drug delivery, and use thereof. Specifically provided is a nanoparticle composition comprising a lipid component, the lipid component comprising a compound represented by formula (I). The nanoparticle composition of the present invention is delivered only at the site of administration.
BOPI
Sede Electrónica
